JP2003534384A5 - - Google Patents

Download PDF

Info

Publication number
JP2003534384A5
JP2003534384A5 JP2001587795A JP2001587795A JP2003534384A5 JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5 JP 2001587795 A JP2001587795 A JP 2001587795A JP 2001587795 A JP2001587795 A JP 2001587795A JP 2003534384 A5 JP2003534384 A5 JP 2003534384A5
Authority
JP
Japan
Prior art keywords
formulation
antagonist
agonist
peptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001587795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/016654 external-priority patent/WO2001091780A1/en
Publication of JP2003534384A publication Critical patent/JP2003534384A/ja
Publication of JP2003534384A5 publication Critical patent/JP2003534384A5/ja
Pending legal-status Critical Current

Links

JP2001587795A 2000-05-26 2001-05-23 神経保護性ペプチド Pending JP2003534384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20765400P 2000-05-26 2000-05-26
US60/207,654 2000-05-26
PCT/US2001/016654 WO2001091780A1 (en) 2000-05-26 2001-05-23 Neuroprotective peptides

Publications (2)

Publication Number Publication Date
JP2003534384A JP2003534384A (ja) 2003-11-18
JP2003534384A5 true JP2003534384A5 (enExample) 2008-07-03

Family

ID=22771463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001587795A Pending JP2003534384A (ja) 2000-05-26 2001-05-23 神経保護性ペプチド

Country Status (11)

Country Link
EP (1) EP1296702A4 (enExample)
JP (1) JP2003534384A (enExample)
CN (1) CN1318084C (enExample)
AU (2) AU2001274904B2 (enExample)
BR (1) BR0111182A (enExample)
CA (1) CA2410453A1 (enExample)
IL (1) IL153079A0 (enExample)
MX (1) MXPA02011727A (enExample)
NZ (1) NZ522924A (enExample)
WO (1) WO2001091780A1 (enExample)
ZA (1) ZA200210304B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
CA2376232A1 (en) 1999-06-14 2000-12-21 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
KR101163683B1 (ko) * 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP2035041B1 (en) 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Conjugates for innate immunotherapy of cancer
US8106154B2 (en) 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
RU2410392C2 (ru) 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
SI2675480T1 (sl) * 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
CN105517561A (zh) * 2013-07-17 2016-04-20 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
TW202024117A (zh) * 2018-09-14 2020-07-01 日商Ｅｐｏ醫藥股份有限公司 抗紅血球生成素受體胜肽
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Similar Documents

Publication Publication Date Title
Pasut et al. PEGylation of proteins as tailored chemistry for optimized bioconjugates
JP6073409B2 (ja) 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
KR101352225B1 (ko) 신규한 엑센딘 변형 및 이들의 콘쥬게이트
US7030218B2 (en) Pseudo native chemical ligation
TW570802B (en) Improved interferon polymer conjugates
JP4157277B2 (ja) 実質的に純粋なヒスチジン結合タンパク質−ポリマー結合体
US20050107297A1 (en) Novel poly(ethylene glycol) modified compounds and uses thereof
KR20060023123A (ko) 폴리(에틸렌 글리콜)-개질된 펩티드 기재 화합물용 신규간격자 부분
CA2480883A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JPH10500693A (ja) 改変型インスリン様増殖因子
EA004791B1 (ru) Композиции на основе слитого белка ob и способы их применения
RS51852B (sr) Modifikovani peptidi kao terapeutski agensi
US20120296072A1 (en) N-terminally chemically modified protein compositions and methods
US20070166278A1 (en) Novel g-csf conjugates
US8906355B2 (en) Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
CN102421447A (zh) 用peg标记干扰素的方法
KR100507796B1 (ko) 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
US6242570B1 (en) Production and use of recombinant protein multimers with increased biological activity
IL273368B2 (en) Composite medical preparations with increased binding capacity to albumin
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
KR100459105B1 (ko) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
ZA200505707B (en) Polymer conjugates of mutated neublastin
CN102724980B (zh) 蛋白-聚合物偶联物的治疗用途
Veronese et al. Custom-tailored pharmacokinetics and pharmacodynamics via chemical modifications of biotech drugs
KR20130137966A (ko) 생체적합성 고분자가 접합된 단백질 및 이의 제조방법